AstraZeneca Secures ZEGFROVY Rights in Up to $1.5B Deal
核心洞察
AstraZeneca completed an exclusive licensing agreement with Dizal Pharmaceutical for ZEGFROVY (搜索), gaining worldwide development and commercialization rights to the lung cancer drug.
The deal includes $600 million upfront plus up to $900 million in milestone payments, with tiered royalties on global sales for Dizal.
ZEGFROVY (搜索), an oral irreversible EGFR (搜索) inhibitor approved in the U.S. and China for second-line EGFR exon 20 insertion NSCLC, is under FDA review for first-line use.
AstraZeneca has completed an exclusive licensing agreement with Dizal Pharmaceutical Co. Ltd. (搜索) for ZEGFROVY (搜索) (sunvozertinib), securing worldwide development and commercialization rights to the lung cancer drug. The transaction includes $600 million upfront and as much as $900 million in additional milestone payments, plus tiered royalties on global sales for Dizal. AstraZeneca said the deal does not affect its 2026 financial guidance.
ZEGFROVY (搜索) is an oral irreversible epidermal growth factor receptor (EGFR (搜索)) inhibitor approved in the U.S. and China as a second-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (搜索) harboring EGFR exon 20 insertion mutations. The drug is already available in China for that indication, and AstraZeneca plans a U.S. launch in the fourth quarter of 2026. The company noted that real-world five-year overall survival for these patients can be as low as 8%, and the drug is listed in the NCCN Clinical Practice Guidelines in Oncology as a subsequent therapy option for advanced or metastatic disease.
AstraZeneca is now pursuing earlier-line use. The FDA has accepted a supplemental New Drug Application for first-line ZEGFROVY (搜索) in EGFR (搜索) exon 20 insertion mutation-positive NSCLC, supported by positive results from the global WU-KONG28 Phase III trial presented at the 2026 American Society of Clinical Oncology Annual Meeting and published simultaneously in The New England Journal of Medicine. A first-line submission is also under review by China's Center for Drug Evaluation, and both regulators have granted Breakthrough Therapy Designation for that use.
Source: MyChesCo